retatrutide trial sign up australia New pharmacological treatments for obesity: incretin analogues, their mechanism of action, efficacy and safety https://www.biopharmadive.com/news/lilly-retatrutide -obesity-osteoarthritis-pain-study-results/807641

Decreases Cardiovascular Events: Reduces rates of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death

Infobase Publishing

Care continues with check-ins, dose adjustments based on how you respond, and direct messaging through the patient portal

Which metabolic pathways does Semaglutide target to reduce appetite

Oral GLP-1 Agonist Orforglipron Shows Promise for Type 2 Diabetes and Weight Management Kennedy Ferruggia, Associate Editor Key Takeaways Orforglipron, a novel oral GLP-1 receptor agonist, shows significant HbA1C reduction and weight loss in patients with T2D, with a safety profile similar to injectable GLP-1 drugs